CJC-1295 + Ipamorelin is a lyophilized research blend (10 mg vial, ≥99% purity) that combines two growth hormone secretagogues acting on two different pituitary receptors. Pepitiva supplies it for in ...
Certificate of Analysis included with every order.
Technical Specifications
Purity
≥99%
Form
Lyophilized powder
Storage
-20°C
Molecular Weight
See Certificate of Analysis
Sequence
See Certificate of Analysis
CAS Number
See Certificate of Analysis
About CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin is a lyophilized research blend (10 mg vial, ≥99% purity) that combines two growth hormone secretagogues acting on two different pituitary receptors. Pepitiva supplies it for in vitro and preclinical research.
What is in the blend
CJC-1295: a growth hormone-releasing hormone (GHRH) analogue. As first described, it is a tetrasubstituted form of human GRF(1-29) with a reactive maleimidopropionamide group on an added C-terminal lysine, which binds serum albumin after injection and extends its plasma half-life.[1] PubChem lists this molecule with formula C165H269N47O46 and 3647.2 g/mol.[11]
Ipamorelin: a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that releases growth hormone through the ghrelin (GHRP) receptor, described as the first secretagogue of this class with selectivity for GH release.[5][12]
Which CJC-1295?
The name CJC-1295 is used both for the albumin-binding molecule above (often labelled "with DAC") and for a version without the reactive group ("without DAC"); the review literature treats them as separate agents.[9] Check the batch Certificate of Analysis for the exact identity and amount of each component.
Evidence for the combination
Each component has its own published literature, but we found no published experimental study that tests CJC-1295 and ipamorelin together; the combination appears in the literature only in reviews of unregulated peptide use.[9][10] Neither peptide is an approved medicine.[10]
For research use only. Not for human consumption.
Quality & Storage
≥99% purity. Lyophilized powder. Storage: -20°C. For research purposes only.
Mechanism of Action
Two receptors, one output
CJC-1295 acts on the GHRH receptor of the anterior pituitary, the receptor used by native GHRH.[1] Ipamorelin acts on a separate receptor: pharmacological profiling with GHRP and GHRH antagonists showed that it, like GHRP-6, releases GH via a GHRP-like receptor.[5] Pairing a GHRH-receptor agonist with a GHRP-receptor agonist is the rationale behind the blend; in healthy men, infusing GHRH together with GHRP-2 produced marked GH release through GHRH-GHRP synergy.[7] That synergy study used GHRP-2, not ipamorelin or CJC-1295.
CJC-1295: albumin binding and duration
In rats, CJC-1295 produced a 4-fold larger GH area under the curve over 2 hours than hGRF(1-29), was detected bound to serum albumin from 15 minutes after injection, and remained in plasma beyond 72 hours.[1] In healthy adults its estimated half-life was 5.8 to 8.1 days.[2]
Ipamorelin: short-acting and selective
In swine, ipamorelin did not raise ACTH or cortisol beyond the levels seen with GHRH, even at doses more than 200-fold above the ED50 for GH release, and it did not affect FSH, LH, prolactin or TSH.[5] In human volunteers it had a terminal half-life of 2 hours and produced a single episode of GH release peaking at about 0.67 hours.[6]
Research Applications
Published findings on each component
CJC-1295 in healthy adults (2006): a single injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days; after multiple doses IGF-I stayed above baseline for up to 28 days, and no serious adverse reactions were reported.[2]
GH pulsatility (2006): one week after CJC-1295, GH pulse frequency and size were unchanged, trough GH rose 7.5-fold, and mean GH and IGF-I rose by 46% and 45%.[3]
GHRH knockout mice (2006): daily CJC-1295 normalized body weight and length, while less frequent administration did not fully normalize growth; pituitary GH mRNA increased.[4]
Ipamorelin pharmacology (1998): GH-releasing potency and efficacy similar to GHRP-6 in rat pituitary cells, in anaesthetised rats and in conscious swine.[5]
Laboratory research applications
GHRH-receptor versus ghrelin-receptor signaling: comparing each pathway alone and together in pituitary cell models.[1][5]
Pulsatile versus basal GH secretion: how sustained GHRH stimulation and short ghrelin-receptor pulses shape the GH profile.[3][6]
Analytical and anti-doping methods: identification of GHRH analogues such as CJC-1295, which is prohibited under section S2 of the WADA Prohibited List.[8]
Single-component controls:ipamorelin is available on its own, and sermorelin and tesamorelin are other GHRH-receptor agonists for comparison.
CJC-1295 and ipamorelin remain investigational, with uncertain safety profiles and product-quality concerns noted in recent reviews.[10] This product is sold for laboratory research only.
Storage & Handling Guidelines
Proper storage and handling are essential to maintain peptide integrity and ensure reliable research results. All Pepitiva Biolabs peptides are supplied as lyophilized (freeze-dried) powder, which provides excellent long-term stability when stored correctly. Store lyophilized peptides at -20°C for long-term storage or 2-8°C for short-term use. Once reconstituted, peptide solutions should be stored at 2-8°C and used within the timeframe specified in the product documentation. Always use sterile bacteriostatic water for reconstitution and handle peptides in a clean laboratory environment to prevent contamination. Avoid repeated freeze-thaw cycles, as thermal stress can cause peptide degradation and loss of biological activity.
Quality Control & Certification
This product is manufactured under strict quality control protocols and has been verified through comprehensive analytical testing. Each batch undergoes reverse-phase HPLC analysis for purity determination and electrospray ionization mass spectrometry (ESI-MS) for molecular identity confirmation. A detailed Certificate of Analysis (COA) is available for download, documenting purity percentage, molecular weight verification, appearance, and recommended storage conditions. Pepitiva Biolabs maintains batch-level traceability from synthesis through delivery, ensuring complete transparency and quality assurance for your research.
Frequently Asked Questions
What is CJC-1295 + Ipamorelin?
A research blend of two growth hormone secretagogues in one lyophilized vial: CJC-1295, a GHRH analogue, and ipamorelin, a selective ghrelin-receptor (GHRP) agonist.
Is the CJC-1295 in this blend with or without DAC?
The name is used for both forms, and they are different molecules. Check the batch Certificate of Analysis for the exact identity of the CJC-1295 component.
Has the CJC-1295 and ipamorelin combination been studied?
Each peptide has published studies, but we found no published experimental study of the two together. GHRH-GHRP synergy has been shown with other peptides (GHRH plus GHRP-2), so the effect of this specific pair is an open research question.
What is the difference between CJC-1295 and ipamorelin?
CJC-1295 acts on the GHRH receptor and, in its albumin-binding form, has a half-life of several days in humans. Ipamorelin acts on the ghrelin (GHRP) receptor and has a half-life of about 2 hours. See ipamorelin.
Is CJC-1295 + Ipamorelin FDA approved?
No. Neither CJC-1295 nor ipamorelin is an approved medicine, and CJC-1295 is prohibited in sport under section S2 of the WADA list. This blend is sold for laboratory research only.
How should CJC-1295 + Ipamorelin be stored?
Keep the lyophilized powder at −20 °C, protected from light and moisture.
Is this product approved for human use?
No. This product is intended exclusively for in vitro scientific research and laboratory use. It is not approved for human or veterinary use, not intended for diagnostic or therapeutic purposes, and should not be administered to humans or animals under any circumstances.
How do I reconstitute this peptide?
Add sterile bacteriostatic water slowly to the vial, directing the stream against the glass wall rather than directly onto the lyophilized powder. Gently swirl the vial until the powder is fully dissolved — do not shake vigorously. The recommended reconstitution volume depends on your desired concentration. Refer to the product documentation for specific guidance.
Can I get a Certificate of Analysis (COA)?
Yes. A Certificate of Analysis is included with every order and is also available for download from the product page. The COA documents HPLC purity, mass spectrometry identity confirmation, batch number, production date, and storage recommendations.
Scientific References
Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PubMed
Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PubMed
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. PubMed
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PubMed
Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. PubMed
Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. PubMed
Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed
Villegas Meza AD, Nocek M, Mitchell BC, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026;14(5):e26.00027. PubMed
PubChem. Ipamorelin, CID 9831659: C38H49N9O5, 711.9 g/mol, CAS 170851-70-4. Source
Sources are peer-reviewed publications indexed in PubMed and trial registrations on ClinicalTrials.gov. Each citation was checked against its PubMed record.
For research use only. Not for human consumption.
Related Peptides
≥98%
Endocrine
Ipamorelin
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that releases growth hormone ...
